MX2022012527A - Vacunas, adjuvantes, y metodos para generar una respuesta inmunitaria. - Google Patents

Vacunas, adjuvantes, y metodos para generar una respuesta inmunitaria.

Info

Publication number
MX2022012527A
MX2022012527A MX2022012527A MX2022012527A MX2022012527A MX 2022012527 A MX2022012527 A MX 2022012527A MX 2022012527 A MX2022012527 A MX 2022012527A MX 2022012527 A MX2022012527 A MX 2022012527A MX 2022012527 A MX2022012527 A MX 2022012527A
Authority
MX
Mexico
Prior art keywords
vaccines
methods
adjuvants
generating
immune response
Prior art date
Application number
MX2022012527A
Other languages
English (en)
Inventor
Sally Ishizaka
Lynn Hawkins
David Evander Anderson
Fabian Gusovsky
Anne-Catherine Fluckiger
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2022012527A publication Critical patent/MX2022012527A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

En la presente descripción se proporcionan vacunas que incluyen antígenos de coronavirus y E6020, así como métodos de mitigación de la infección por coronavirus mediante la administración de esas vacunas.
MX2022012527A 2020-04-06 2021-04-06 Vacunas, adjuvantes, y metodos para generar una respuesta inmunitaria. MX2022012527A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063005908P 2020-04-06 2020-04-06
PCT/US2021/026058 WO2021207281A2 (en) 2020-04-06 2021-04-06 Vaccines, adjuvants, and methods of generating an immune response

Publications (1)

Publication Number Publication Date
MX2022012527A true MX2022012527A (es) 2023-03-13

Family

ID=75747059

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012527A MX2022012527A (es) 2020-04-06 2021-04-06 Vacunas, adjuvantes, y metodos para generar una respuesta inmunitaria.

Country Status (11)

Country Link
US (1) US20230149537A1 (es)
EP (1) EP4132577A2 (es)
JP (1) JP2023520603A (es)
KR (1) KR20230034936A (es)
CN (1) CN115916254A (es)
AU (1) AU2021252972A1 (es)
BR (1) BR112022020298A2 (es)
CA (1) CA3179739A1 (es)
IL (1) IL297093A (es)
MX (1) MX2022012527A (es)
WO (1) WO2021207281A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022051859A1 (en) * 2020-09-11 2022-03-17 Manuel Caruso Pseudotyped retroviral particles for inducing immunity against coronavirus infections
CN117440825A (zh) * 2020-12-16 2024-01-23 芬雷疫苗学院 基于SARS-CoV-2病毒的受体结合结构域的疫苗组合物在保护性免疫的发展中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201750A1 (en) 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
WO2007005583A1 (en) * 2005-06-30 2007-01-11 Eisai Co., Ltd. Compounds for preparing immunological adjuvant
BR112015018014A2 (pt) * 2013-02-01 2017-07-11 Glaxosmithkline Biologicals Sa liberação intradérmica de composições imunológicas compreendendo agonistas do receptor do tipo toll

Also Published As

Publication number Publication date
EP4132577A2 (en) 2023-02-15
KR20230034936A (ko) 2023-03-10
CN115916254A (zh) 2023-04-04
AU2021252972A1 (en) 2022-11-10
BR112022020298A2 (pt) 2022-12-20
JP2023520603A (ja) 2023-05-17
WO2021207281A3 (en) 2021-12-16
WO2021207281A2 (en) 2021-10-14
IL297093A (en) 2022-12-01
CA3179739A1 (en) 2021-10-14
US20230149537A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
MX2022012527A (es) Vacunas, adjuvantes, y metodos para generar una respuesta inmunitaria.
MX2022009989A (es) Composiciones inmunogenicas y vacunas para covid-19 vectorizadas por sarampion.
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
MX2020013153A (es) Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana.
PH12019501766A1 (en) Porcine coronavirus vaccines
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
MX2021009105A (es) Toxinas apxia, apxiia y apxiiia inactivadas.
NZ587798A (en) Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2023003784A (es) Peptido derivado de proteina de sars-cov-2 y vacuna que lo contiene.
CL2009000287A1 (es) Composicion que comprende un alfavirus salmonideo (sav) inactivado y al menos un componente seleccionado de una bacteria muerta/inactivada, otro virus inactivado, un hongo, un parasito y un material antigenico derivado de la bacteria, virus, hongo o parasito anterior; metodo para elaborar la composicion y uso del sav.
CL2020002876A1 (es) Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)
MX2022010781A (es) Vacuna contra el virus sars-cov-2 con adyuvante cpg.
MX2021005303A (es) Composiciones inmunogenicas.
MX2017000154A (es) Sistema de rinovacunacion de la vacuna contra la influenza.
MX2021009790A (es) Adyuvantes y formulaciones para vacunas.
NZ614147A (en) Equine rhinitis vaccine
MX2022004869A (es) Vacuna de particulas similares al virus chikungunya y metodos de uso de la misma.
MX2022003090A (es) Vacuna combinada para ser administrable intradermicamente.
MX2021015643A (es) Vacuna alogénica contra el virus de inmunodeficiencia humana (vih) basada en linfocitos t para inducir la inmunidad celular y humoral.
MX2023002356A (es) Vacunas contra la covid-19 con coadyuvantes en emulsion de escualeno que contiene tocoferol.
MX2022012447A (es) Vacuna inactivada contra el virus sars-cov-2.
MX2023008049A (es) Peptido derivado de proteina de sars-cov-2 y vacuna que lo contiene.
PH12020550948A1 (en) Vaccines against hendra and nipah virus infection